Harvey Berger Named CEO of Arena Bioworks
- arena BioWorks, the aspiring drug discovery institute backed by $500 million in funding from prominent billionaires, has appointed Harvey Berger as its new Chief Executive Officer.
- The appointment of Harvey Berger is especially noteworthy given his extensive experience in the biotech industry.He co-founded ARIAD Pharmaceuticals in 1991 with Stuart Schreiber, and successfully guided ARIAD...
- Schreiber, a renowned chemist, has a distinguished career in academic research.
“`html
Arena BioWorks Appoints Harvey Berger as CEO, Signaling Strategic Shift
arena BioWorks, the aspiring drug discovery institute backed by $500 million in funding from prominent billionaires, has appointed Harvey Berger as its new Chief Executive Officer. This leadership change, announced Monday, marks a shift in focus for the organization and reunites Berger with longtime collaborator Stuart Schreiber, who transitions to the role of Chief Scientific Officer. STAT News first reported the news.
The Leadership Transition: berger and Schreiber’s History
The appointment of Harvey Berger is especially noteworthy given his extensive experience in the biotech industry.He co-founded ARIAD Pharmaceuticals in 1991 with Stuart Schreiber, and successfully guided ARIAD through the approval of its first drug, brigatinib, a treatment for non-small cell lung cancer. Ariad Pharmaceuticals was later acquired by Takeda Pharmaceutical in 2017 for $5.2 billion.Reuters reported on the acquisition.
Schreiber, a renowned chemist, has a distinguished career in academic research. He co-founded the Broad Institute of MIT and Harvard, a leading biomedical research institution, and played a pivotal role in establishing Arena BioWorks. His move to Chief Scientific Officer allows him to concentrate on the scientific direction of the institute, while Berger focuses on operational leadership and strategic growth.
Arena BioWorks: A Bold Venture in Drug Discovery
Launched in January 2024, Arena BioWorks represents a important investment in early-stage drug discovery. The $500 million in funding comes from a consortium of billionaires including Nat Simons, Dustin Moskovitz, and patrick and Alexandra Collison.STAT News detailed the initial funding round.
The institute aims to tackle challenging drug discovery projects that might potentially be overlooked by larger pharmaceutical companies. Its approach emphasizes a collaborative environment, bringing together experts in chemistry, biology, and data science. Arena BioWorks is focused on creating new medicines for a range of diseases, with an initial emphasis on oncology, neurodegeneration, and infectious diseases.
The initial funding is intended to support Arena BioWorks for at least seven years, providing a ample runway for research and advancement.The institute plans to employ approximately 100 scientists and staff by the end of 2024.
Implications of the CEO change
The transition from Schreiber to Berger suggests a potential shift in Arena BioWorks’ strategy. Schreiber, with his academic background, likely prioritized foundational research and scientific innovation. Berger, as a seasoned biotech executive, is expected to focus on translating those discoveries into tangible drug candidates and navigating the complexities of clinical development and commercialization.
This change could also indicate a desire to attract further investment from venture capital firms and pharmaceutical companies. A strong CEO with a proven track record can instill confidence in potential partners and investors.
Key Players in Arena BioWorks
| Name | Title | Background |
|---|